Piper Sandler Discusses Ventyx Biosciences (VTYX) KOL Takeaways Into Upcoming Deucravacitinib PDUFA
Tweet Send to a Friend
Piper Sandler analyst Yasmeen Rahimi reiterated an Overweight rating and $50.00 price target on Ventyx Biosciences Inc (NASDAQ: VTYX) ahead ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE


